Ashish Sethi, Raj Moses S, Monga Dulabh, Finley Gene
Department of Hematology and Oncology, Allegheny Health Network, Pittsburgh, USA.
Cureus. 2022 Jul 13;14(7):e26824. doi: 10.7759/cureus.26824. eCollection 2022 Jul.
Fluoropyrimidines (FP's) such as fluorouracil (5-FU) and capecitabine are antimetabolites widely used in many solid tumors. FPs side effects are caused mainly by a lack of dihydropyrimidine dehydrogenase (DPD) enzyme. It has been noticed that treatment with infusional regimens of 5-FU is associated with more adverse events (AE) compared to bolus forms. Here, we report two cases of unusual side effects seen with infusional 5-FU and capecitabine and how early intervention by withholding ongoing treatment can help in preventing progression and mortality.
氟嘧啶（FP），如氟尿嘧啶（5-FU）和卡培他滨，是广泛应用于多种实体瘤的抗代谢药物。FP的副作用主要由二氢嘧啶脱氢酶（DPD）缺乏引起。人们已经注意到，与推注剂型相比，5-FU持续输注方案治疗会伴随更多不良事件（AE）。在此，我们报告两例5-FU和卡培他滨持续输注时出现的罕见副作用病例，以及通过暂停正在进行的治疗进行早期干预如何有助于预防病情进展和死亡。
